AQW 051

Drug Profile

AQW 051

Alternative Names: AQW-051

Latest Information Update: 05 Nov 2015

Price : $50

At a glance

  • Originator Novartis
  • Class Antipsychotics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders; Drug-induced dyskinesia

Most Recent Events

  • 06 Aug 2015 Vanda Pharmaceuticals is evaluating potential indications for AQW 051 following in-licensing the product from Novartis
  • 23 Dec 2014 AQW 051 licensed to Vanda Pharmaceuticals worldwide
  • 31 Dec 2013 Novartis completes a phase II trial in Cognition disorders in USA (NCT01730768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top